Skip to main content

NASDAQ:CLCD Investor Notice: Investigation of Takeover of CoLucid Pharmaceuticals Inc

San Diego, CA -- (SBWIRE) -- 01/24/2017 -- The acquisition of CoLucid Pharmaceuticals Inc is under investigation over potential wrongdoing. The investigation was announced for investors, who currently hold NASDAQ:CLCD shares, concerning whether the takeover of CoLucid Pharmaceuticals Inc by Eli Lilly and Company for $46.50 per share is unfair.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.